Detalles de la búsqueda
1.
Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma.
Ann Hematol
; 100(3): 691-698, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33528609
2.
Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations.
Eur J Haematol
; 100(5): 395-402, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29360184
3.
Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Biol Blood Marrow Transplant
; 22(6): 1037-1042, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26970381
4.
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure.
Hemasphere
; 4(3): e401, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32647803
5.
A Phase 2 Study of Nivolumab Using a Fixed Dose of 40âmg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma.
Hemasphere
; 4(5): e480, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33062947
6.
High prevalence of CD3, NK, and NKT cells in the graft predicts adverse outcome after matched-related and unrelated transplantations with post transplantation cyclophosphamide.
Bone Marrow Transplant
; 55(3): 544-552, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31541204
7.
An inter-laboratory comparison of PNH clone detection by high-sensitivity flow cytometry in a Russian cohort.
Hematology
; 20(1): 31-8, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24666187
8.
Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naïve patients.
Leuk Lymphoma
; 60(9): 2316-2319, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30712423
Resultados
1 -
8
de 8
1
Próxima >
>>